Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Egbring

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Thrombosis Et Diathesis Haemorrhagica|November 15, 1975
Proceedings: A new case of dysfibrinogenemia, fibrinogen MarburgG Fuchs, R Egbring, K Havemann
Progress in Clinical and Biological Research|January 1, 1989
Antithrombin III and plasma substitution in septic shockR Seitz, M Wolf, R Egbring
APMIS. Supplementum|January 1, 1990
Activation of blood coagulation and endothelial dysfunction in patients with Wegener's granulomatosis and related disordersR Egbring, R Seitz, K Andrassy
Advances in Experimental Medicine and Biology|January 1, 1984
Alpha-2-plasmin-inhibitor inactivation by human granulocyte elastaseM Gramse, K Havemann, R Egbring
Blut|February 1, 1977
Fibrinogen Marburg a new genetic variant of fibrinogenG Fuchs, R Egbring, K Havemann
Seminars in Thrombosis and Hemostasis|January 1, 1996
Factor XIII deficiency: pathogenic mechanisms and clinical significanceR Egbring, A Kröniger, R Seitz
Klinische Wochenschrift|May 16, 1980
Structure of fibrin and fibrinmonomer in renal and hepatic failureH G Klingemann, R Egbring, K Havemann
Behring Institute Mitteilungen|February 1, 1986
[Disturbances in coagulation, fibrinolytic and complement systems in septic shock]H E Karges, R Egbring, D Merte
Scandinavian Journal of Haematology|October 1, 1981
Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myelomaH G Klingemann, R Egbring, K Havemann
Arzneimittel-Forschung|January 1, 1980
[Effects of polymyxin B and E (colistin) on blood coagulation, thrombocyte function, and fibrin structure (author's transl)]H G Klingemann, R Egbring, H Kaffarnik
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Thrombosis Et Diathesis Haemorrhagica|November 15, 1975
Proceedings: A new case of dysfibrinogenemia, fibrinogen MarburgG Fuchs, R Egbring, K Havemann
Progress in Clinical and Biological Research|January 1, 1989
Antithrombin III and plasma substitution in septic shockR Seitz, M Wolf, R Egbring
APMIS. Supplementum|January 1, 1990
Activation of blood coagulation and endothelial dysfunction in patients with Wegener's granulomatosis and related disordersR Egbring, R Seitz, K Andrassy
Advances in Experimental Medicine and Biology|January 1, 1984
Alpha-2-plasmin-inhibitor inactivation by human granulocyte elastaseM Gramse, K Havemann, R Egbring
Blut|February 1, 1977
Fibrinogen Marburg a new genetic variant of fibrinogenG Fuchs, R Egbring, K Havemann
Seminars in Thrombosis and Hemostasis|January 1, 1996
Factor XIII deficiency: pathogenic mechanisms and clinical significanceR Egbring, A Kröniger, R Seitz
Klinische Wochenschrift|May 16, 1980
Structure of fibrin and fibrinmonomer in renal and hepatic failureH G Klingemann, R Egbring, K Havemann
Behring Institute Mitteilungen|February 1, 1986
[Disturbances in coagulation, fibrinolytic and complement systems in septic shock]H E Karges, R Egbring, D Merte
Scandinavian Journal of Haematology|October 1, 1981
Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myelomaH G Klingemann, R Egbring, K Havemann
Arzneimittel-Forschung|January 1, 1980
[Effects of polymyxin B and E (colistin) on blood coagulation, thrombocyte function, and fibrin structure (author's transl)]H G Klingemann, R Egbring, H Kaffarnik
Pageof 10